NTI

2.99%

6.9¢ neurotech international limited

By the way when I said above I made a purchase subsequently...

First 4 Last

Share
Profile

Follow
Red bar

1,355 Posts.

816

03/05/18

09:08

Post #: 32848030
Share

Originally posted by Red bar ↑

Thanks for your analysis.
This is one of my points I was making when observing last time...
NTI ran up to 50 cents shortly after it IPO'd on hype. Many people were fascinated by the product and thought it still had legs without knowing how long it was actually was going to take to get to production faze and pass clinical milestones etc. I too was one of the casualties and sold out at a loss to help offset my CGT last financial year. My purchase at the time was in the low 40s, sold in the high 20s. Decided to revisit this puppy and make a purchase substantially higher to my previous purchase based on the preliminary outcomes. Timed my trade closer to the event of the announcement of the clinical results being announced. Was then hit with a out of the blue delay announcement stating that company had no control of the delay as they were awaiting the results to be published into a medical journal and be cited by other professionals in the neuroscience field over the connin FEW months. Guess what?! quite a few people fled and share price subsequently deflated. Today's day and age people are so impatient and want money/ results yesterday. In my opinion being patient on the ASX is where you can make some of the BIG BUCKS! Lots of supply above 20 cents was munched through buy the preliminary Cookie Monster clinical trial outcomes dated on the 27/09/2017. An announcement validating the results will most likely see a double up of volume at minimum over the previous preliminary clinical trial outcomes announcement and an increase back to around the $0.50 level probably Within a day or two but I'd expect volatility to come through with such a gap up followed by More groundbreaking announcements by the company there after... For example once the technology is validated out of the USA clinical trial, ramping up throughout Europe will be inevitable. Companies, individuals, parents etc love clarity and confirmation especially when dealing with once son or daughter..
Our company is clearly preparing for this based on the latest quarterly report...
Lodgment to the FDA, FDA clearance would most probably happen within a few after logging.

Well it's the start of a new month now so perhaps results will be published into this month's medical journal. It's been a few months now since the results were obtained by the Carrick Institute..
We continue to wait, meanwhile other people have an opportunity here to jump in now and potentially reap BIG rewards..

NTI looks the goods...

All IMO

Cheers

Red bar

Expand

By the way when I said above I made a purchase subsequently higher to my previous purchase - I'm talking about I made a larger investment with in this company dollar value wise...
By the way I've averaged down twice since buying back in. That's how confident I am that the coming results will be very positive!!

Cheers

Red bar

NTI Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

There are more pages in this discussion • 7 more messages in this thread...

First 4 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 6.9¢		Change 0.002(2.99%)		Mkt cap ! $64.55M

Open	High	Low	Value	Volume
6.7¢	7.2¢	6.7¢	$45.29K	648.2K

Buyers (Bids)

No.	Vol.	Price($)
3	684701	6.6¢

Sellers (Offers)

Price($)	Vol.	No.
6.9¢	100000	1

View Market Depth

No.	Vol.	Price($)
4	589299	0.070
1	36231	0.069
5	240000	0.068
2	255000	0.067
3	262000	0.066

Price($)	Vol.	No.
0.072	100000	1
0.074	40000	1
0.075	738582	2
0.076	90000	1
0.077	190000	3

Last trade - 15.37pm 22/11/2024 (20 minute delay)

NTI (ASX) Chart

By the way when I said above I made a purchase subsequently...

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Sales growth pushes Lovisa's fortunes (and shares) upwards

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

By the way when I said above I made a purchase subsequently...

Top Stories

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Sales growth pushes Lovisa's fortunes (and shares) upwards

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News